The antiplatelet effects of nitrates: Is it of clinical significance in patients with cardiovascular disease?

Cardiology in Review

Volumn 18, Issue 4, 2010, Pages 198-203

  Zhou, Rui Hai ^a,b   Frishman, William H ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b SHANDONG UNIVERSITY   (China)

^c WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

Nitrates; Nitrovasodilators; Platelet activation; Sodium nitroprusside; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; CLOPIDOGREL; GLYCEROL 1 NITRATE; GLYCERYL TRINITRATE; LISINOPRIL; NITRATE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PENTAERYTHRITYL TETRANITRATE; PLACEBO; THIENOPYRIDINE DERIVATIVE; THROMBOXANE SYNTHASE INHIBITOR; VERAPAMIL; ANTITHROMBOCYTIC AGENT; NITRIC ACID DERIVATIVE; VASODILATOR AGENT;

ANGINA PECTORIS; ARTERY DILATATION; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BLOOD FLOW; DRUG ACTIVATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HEART VENTRICLE OVERLOAD; HUMAN; MEDICAL RESEARCH; NONHUMAN; OXIDATIVE STRESS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; VEIN DILATATION; CARDIOVASCULAR DISEASES; DRUG EFFECTS; DRUG TOLERANCE; PATHOPHYSIOLOGY; THROMBOCYTE; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DRUG TOLERANCE; ENDOTHELIUM, VASCULAR; HUMANS; NITRATES; OXIDATIVE STRESS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 77953996831     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181d74582     Document Type: Review

References (85)

1. Langford EJ, Wainwright RJ, Martin JF. Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Arterioscler Thromb Vasc Biol. 1996;16:51-55.
2. Smitherman TC, Milam M, Woo J, et al. Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. Am J Cardiol. 1981;48: 395-402.
3. Fitzgerald D, Roy L, Catella F, et al. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
4. Gray RP, Hendra TJ, Patterson DL, et al. "Spontaneous" platelet aggregation in whole blood in diabetic and non diabetic survivors of acute myocardial infarction. Thromb Haemost. 1993;70:932-936.
5. Becker RC, Tracy RP, Bovill EG, et al. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. TIMI-III Thrombosis and Anticoagulation Group. Coron Artery Dis. 1994;5:339-345.
6. Trip M, Cats V, van Capelle F, et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990;322:1549-1554.
7. Freedman JE, Ting B, Hankin B, et al. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation. 1998;98: 1481-1486.
8. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 1981;47:525-531.
9. Kyrle PA, Korninger C, Gossinger H, et al. Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thromb Haemost. 1985;54:521-523.
10. Lip G. Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy. Postgrad Med J. 1996;72:731-738.
11. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336:251-257.
12. Dries D, Rosenberg Y, Waclawiw M, et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol. 1997;29:1074-1080.
13. Freudenberger RS, Hellkamp AS, Halperin JL, et al. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2007;115:2637-2641.
14. Brown BG, Bolson E, Petersen RB, et al. The mechanisms of nitroglycerin action: stenosis vasodilatation as a major component of the drug response. Circulation. 1981;64:1089-1097.
15. Ginsburg R, Lamb IH, Schroeder JS, et al. Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm. Am Heart J. 1982;103:44-49.
16. Berglund H, Luo H, Nishioka T, et al. Preserved vasodilatory response to nitroglycerin in saphenous vein bypass grafts. Circulation. 1996;94:2871-2876.
17. Cohen MV, Downey JM, Sonnenblick EH, et al. The effects of nitroglycerin on coronary collaterals and myocardial contractility. J Clin Invest. 1973;52: 2836-2847.
18. Bache RJ, Ball RM, Cobb FR, et al. Effects of nitroglycerin on transmural myocardial blood flow in the unanesthetized dog. J Clin Invest. 1975;55: 1219-1228.
19. Hampton JR, Harrison MJ, Honour AJ, et al. Platelet behaviour and drugs used in cardiovascular disease. Cardiovasc Res. 1967;1:101-107.
20. Gebalska J, Wolk R, Ceremuzynski L. Isosorbide dinitrate inhibits platelet adhesion and aggregation in nonthrombolyzed patients with acute myocardial infarction. Clin Cardiol. 2000;23:837-841.
21. Zhou R, Zhu Y, Lu T, et al. Effects of isosobide dinitrate on platelet aggregation in vitro and in vivo in patients with coronary artery disease. Chin J Clin Cardiol. 1995;11:97-98.
22. Zhou R, Liu J, Xie M, et al. Effects of sodium nitroprusside on platelet aggregation in patients with congestive heart failure. Chin Crit Care Med. 1998;10:32-34.
23. Zhou R, Zhang Y, Su R, et al. Effects of sodium nitroprusside on platelet aggregation in patients undergoing heart valve replacement. Chin J Thorac Cardiovasc Surg. 1998;14:10-11.
24. Lacoste LL, Theroux P, Lidon RM, et al. Antithrombotic properties of transdermal nitroglycerin in stable angina pectoris. Am J Cardiol. 1994;73: 1058-1062.
25. Diodati J, Theroux P, Latour JG, et al. Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. Am J Cardiol. 1990;66:683-688.
26. Karlberg KE, Saldeen T, Wallin R, et al. Intravenous nitroglycerin reduces ischaemia in unstable angina pectoris: a double-blind placebo-controlled study. J Intern Med. 1998;243:25-31.
27. Chirkov YY, Naujalis JI, Barber S, et al. Reversal of human platelet aggregation by low concentrations of nitroglycerin in vitro in normal subjects. Am J Cardiol. 1992;70:802-806.
28. Chirkov YY, Naujalis JI, Sage RE, et al. Antiplatelet effects of nitroglycerin in healthy subjects and in patients with stable angina pectoris. J Cardiovasc Pharmacol. 1993;21:384-389.
29. Loscalzo J. Antiplatelet and antithrombotic effects of organic nitrates. Am J Cardiol. 1992;70:18B-22B.
30. Lam JY, Chesebro JH, Fuster V. Platelets, vasoconstriction, and nitroglycerin during arterial wall injury. A new antithrombotic role for an old drug. Circulation. 1988;78:712-716.
31. Sasaki Y, Seki J, Giddings JC, et al. Effects of NO-donors on thrombus formation and microcirculation in cerebral vessels of the rat. Thromb Haemost. 1996;76:111-117.
32. Yao SK, Akhtar S, Scott-Burden T, et al. Endogenous and exogenous nitric oxide protect against intracoronary thrombosis and reocclusion after thrombolysis. Circulation. 1995;92:1005-1010.
33. Johnstone MT, Lam JY, Lacoste L, et al. Methylene blue inhibits the antithrombotic effect of nitroglycerin. J Am Coll Cardiol. 1993;21:255-259.
34. Folts JD, Stamler J, Loscalzo J. Intravenous nitroglycerin infusion inhibits cyclic blood flow responses caused by periodic platelet thrombus formation in stenosed canine coronary arteries. Circulation. 1991;83:2122-2127.
35. Plotkine M, Allix M, Guillou J, et al. Oral administration of isosorbide dinitrate inhibits arterial thrombosis in rats. Eur J Pharmacol. 1991;201:115-116.
36. Werns SW, Rote WE, Davis JH, et al. Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis. Am Heart J. 1994;127:727-737.
37. Rovin JD, Stamler JS, Loscalzo J, et al. Sodium nitroprusside, an endothelium- derived relaxing factor congener, increases platelet cyclic GMP levels and inhibits epinephrine-exacerbated in vivo platelet thrombus formation in stenosed canine coronary arteries. J Cardiovasc Pharmacol. 1993;22:626-631.
38. Helisch A, Frishman WH, Hays RM, et al. Nitric oxide donors in the treatment of cardiovascular diseases. In: Frishman WH, Sonnenblick EH, eds. Cardiovascular Pharmacotherapeutics. New York, NY: McGraw- Hill; 1997:739-756.
39. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2002;99:8306-8311.
40. Chen Z, Foster MW, Zhang J, et al. An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2005;102:12159-12164.
41. Chen Z, Stamler JS. Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc Med. 2006;16:259-265.
42. Singh S, Fritze G, Fang BL, et al. Inheritance of mitochondrial aldehyde dehydrogenase: genotyping in Chinese, Japanese and South Korean families reveals dominance of the mutant allele. Hum Genet. 1989;83:119-121.
43. Li Y, Zhang D, Jin W, et al. Mitochondrial aldehyde dehydrogenase-2 (ALDH2) Glu504Lys polymorphism contributes to the variation in efficacy of sublingual nitroglycerin. J Clin Invest. 2006;116:506-511.
44. Mackenzie IS, Maki-Petaja KM, McEniery CM, et al. Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans. Arterioscler Thromb Vasc Biol. 2005;25:1891-1895.
45. Wenzel P, Hink U, Oelze M, et al. Number of nitrate groups determines reactivity and potency of organic nitrates: a proof of concept study in ALDH-2-/- mice. Br J Pharmacol. 2007;150:526-533.
46. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res. 2007;100:1261-1275.
47. Frishman W, Lerner R, Klein M, et al. Antiplatelet and antithrombotic drugs. In: Frishman W, Sonnenblick E, Sica De, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York, NY: McGraw Hill; 2003:259-299.
48. Loscalzo J. N-Acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. J Clin Invest. 1985;76:703-708.
49. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation. 2007;115:2196-2207.
50. Faraday N, Yanek LR, Mathias R, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation. 2007;115:2490-2496.
51. Nguyen T, Frishman WH, Nawarskas J, et al. Variability of response to clopidogrel: possible mechanisms and clinical implications. Cardiol Rev. 2006;14:136-142.
52. Hanjis C, Frishman WH, Lerner RG. Aspirin resistance: mechanisms and clinical implications. Cardiol Rev. 2006;14:18-25.
53. Muscara MN, Wallace JL. Nitric Oxide. V. Therapeutic potential of nitric oxide donors and inhibitors. Am J Physiol. 1999;276:G1313-G1316.
54. Whittle BJ. Nitric oxide-modulating agents for gastrointestinal disorders. Expert Opin Investig Drugs. 2005;14:1347-1358.
55. Miller MR, Megson IL. Recent developments in nitric oxide donor drugs. 2007;151:305-321.
56. Yusuf S, Collins R, MacMahon S, et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet. 1988;1:1088-1092.
57. Durrer JD, Lie KI, van Capelle FJ, et al. Effect of sodium nitroprusside on mortality in acute myocardial infarction. N Engl J Med. 1982;306:1121-1128.
58. Cohn JN, Franciosa JA, Francis GS, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med. 1982;306:1129-1135.
59. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994;343:1115-1122.
60. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669-685.
61. Mahmarian JJ, Moye LA, Chinoy DA, et al. Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction: results of a multicenter prospective randomized, double- blind, placebo-controlled trial. Circulation. 1998;97:2017-2024.
62. Kanamasa K, Hayashi T, Takenaka T, et al. Continuous long-term dosing with oral slow-release isosorbide dinitrate does not reduce incidence of cardiac events in patients with healed myocardial infarction. Clin Cardiol. 2001;24:608-614.
63. Ishikawa K, Kanamasa K, Ogawa I, et al. Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. Jpn Circ J. 1996;60:779-788.
64. Ishikawa K, Yamamoto T, Kanamasa K, et al. Intermittent nitrate therapy for prior myocardial infraction does not induce rebound angina nor reduce cardiac events. Intern Med. 2000;39:1020-1026.
65. Nakamura Y, Moss AJ, Brown MW, et al. Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J. 1999;138:577-585.
66. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618-628.
67. Thomas GR, DiFabio JM, Gori T, et al. Once daily therapy with isosorbide- 5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol. 2007;49:1289-1295.
68. Schulz E, Tsilimingas N, Rinze R, et al. Functional and biochemical analysis of endothelial (Dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation. 2002;105:1170-1175.
69. Gutterman DD. Combating nitrate tolerance: a novel endogenous mechanism. Arterioscler Thromb Vasc Biol. 2007;27:1673-1676.
70. Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317: 799-804. (Pubitemid 17136471)
71. Watanabe H, Kakihana M, Ohtsuka S, et al. Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation. 1997;96:2545-2550.
72. Otto A, Fontaine D, Fontaine J, et al. Rosuvastatin treatment protects against nitrate-induced oxidative stress. J Cardiovasc Pharmacol. 2005;46:177-184.
73. Inoue T, Takayanagi K, Hayashi T, et al. Fluvastatin attenuates nitrate tolerance in patients with ischemic heart disease complicating hypercholesterolemia. Int J Cardiol. 2003;90:181-188.
74. Gori T, Saunders L, Ahmed S, et al. Effect of folic acid on nitrate tolerance in healthy volunteers: differences between arterial and venous circulation. J Cardiovasc Pharmacol. 2003;41:185-190.
75. Unger P, Berkenboom G, Fontaine J. Interaction between hydralazine and nitrovasodilators in vascular smooth muscle. J Cardiovasc Pharmacol. 1993; 21:478-483.
76. Munzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest. 1996;98:1465-1470.
77. Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:1575-1580.
78. Bauer JA, Fung HL. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation. 1991;84:35-39.
79. Carson P, Ziesche S, Johnson G, et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178-187.
80. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
81. Taylor AL, Ziesche S, Yancy CW, et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation. 2007;115:1747-1753.
82. Mollnau H, Wenzel P, Oelze M, et al. Mitochondrial oxidative stress and nitrate tolerance-comparison of nitroglycerin and pentaerithrityl tetranitrate in Mn-SOD-/- mice. BMC Cardiovasc Disord. 2006;6:44.
83. Rossiello MR, Momi S, Caracchini R, et al. A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. J Thromb Haemost. 2005;3:2554-2562.
84. Zafar MU, Vilahur G, Choi BG, et al. A novel anti-ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects. J Thromb Haemost. 2007;5:1195-1200.
85. Vilahur G, Baldellou MI, Segales E, et al. Inhibition of thrombosis by a novel platelet selective S-nitrosothiol compound without hemodynamic side effects. Cardiovasc Res. 2004;61:806-816.